Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 ± 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week 0, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusions: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.
Abstract
Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 ± 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week 0, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusions: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.
참고문헌 (35)
- Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
- Hekking PP, "The prevalence of severe refractory asthma", J Allergy Clin Immunol, 135, pp.896~902 (2015)
- Sadatsafavi M, "Direct health care costs associated with asthma in British Columbia", Can Respir J, 17, pp.74~80 (2010)
- Eun-young Lee, "Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002–2015: A Nationwide, Population-Based Study", Allergy, Asthma & Immunology Research, 12(3), pp.467~484 (2020), 대한천식알레르기학회
- McGregor MC, "Role of biologics in asthma", Am J Respir Crit Care Med, 199, pp.433~445 (2019)
- Merritt L. Fajt, "Development of New Therapies for Severe Asthma", Allergy, Asthma & Immunology Research, 9(1), pp.3~14 (2017), 대한천식알레르기학회
- 박해심, "Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma", Allergy, Asthma & Immunology Research, 11(4), pp.508~518 (2019), 대한천식알레르기학회
- Easthope S, "Omalizumab", Drugs, 61, pp.253~260 (2001)
- Buhl R, "Omalizumab provides longterm control in patients with moderate-to-severe allergic asthma", Eur Respir J, 20, pp.73~78 (2002)
- Buhl R, "The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma", Eur Respir J, 20, pp.1088~1094 (2002)
- Bousquet J, "Predicting and evaluating response to omalizumab in patients with severe allergic asthma", Respir Med, 101, pp.1483~1492 (2007)
- Busse WW, "Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma : a pooled analysis", Curr Med Res Opin, 23, pp.2379~2386 (2007)
- Costello RW, "Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs", Ir J Med Sci, 180, pp.637~641 (2011)
- Hanania NA, "Omalizumab in severe allergic asthma inadequately controlled with standard therapy : a randomized trial", Ann Intern Med, 154, pp.573~582 (2011)
- Barnes N, "Effectiveness of omalizumab in severe allergic asthma : a retrospective UK real-world study", J Asthma, 50, pp.529~536 (2013)
- Humbert M, "Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy(GINA 2002 step 4 treatment) : INNOVATE", Allergy, 60, pp.309~316 (2005)
- Bousquet J, "Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma", Chest, 125, pp.1378~1386 (2004)
- 김민혜, "Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry", Allergy, Asthma & Immunology Research, 11(1), pp.43~54 (2019), 대한천식알레르기학회
- 이지호, "Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea", Allergy, Asthma & Immunology Research, 10(2), pp.121~130 (2018), 대한천식알레르기학회
- Hanania NA, "Exploring the effects of omalizumab in allergic asthma : an analysis of biomarkers in the EXTRA study", Am J Respir Crit Care Med, 187, pp.804~811 (2013)
- Park JW, "Multi-center study for the utilization of quality of life questionnaire for adult Korean asthmatics(QLQAKA)", Korean J Asthma Allergy Clin Immunol, 20, pp.467~480 (2000)
- Busse WW, "Biological treatments for severe asthma : a major advance in asthma care", Allergol Int, 68, pp.158~166 (2019)
- Pavord ID, "Emerging biologics in severe asthma", Immunol Allergy Clin North Am, 36, pp.609~623 (2016)
- 조유숙, "Dilemma of Asthma Treatment in Mild Patients", Tuberculosis and Respiratory Diseases, 82(3), pp.190~193 (2019), 대한결핵및호흡기학회
- Ioana Agache, "Critical Points on the Use of Biologicals in Allergic Diseases and Asthma", Allergy, Asthma & Immunology Research, 12(1), pp.24~41 (2020), 대한천식알레르기학회
- Godar M, "Personalized medicine with biologics for severe type 2 asthma : current status and future prospects", MAbs, 10, pp.34~45 (2018)
- Michael Dreher, "Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists", Inhaled Corticosteroid, 2018, pp.81(1), 1~5[DOI]
- de Llano LP, "Effects of omalizumab in non-atopic asthma : results from a Spanish multicenter registry", J Asthma, 50, pp.296~301 (2013)
- Garcia G, "A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma", Chest, 144, pp.411~419 (2013)
- Casale TB, "Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma", Allergy, 73, pp.490~497 (2018)
- Katsaounou P, "Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma", Respir Med, 150, pp.51~62 (2019)
- Humbert M, "Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count : the STELLAIR study", Eur Respir J, 51, pp.1702523~ (2018)
- Pelaia C, "Omalizumab, the first available antibody for biological treatment of severe asthma : more than a decade of real-life effectiveness", Ther Adv Respir Dis, 12, pp.1753466618810192~ (2018)
- Bousquet J, "Persistency of response to omalizumab therapy in severe allergic(IgE-mediated)asthma", Allergy, 66, pp.671~678 (2011)